International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationProspective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy
Introduction
Liver cancer generally portends poor prognosis. Metastatic disease is the most common cause and may develop in 40-50% of adult primary cancers, most commonly arising from colorectal, lung, or breast primary. Primary liver cancer incidence, mostly hepatocellular carcinoma (HCC), is increasing in North America owing to increasing hepatitis C and cirrhosis from nonalcoholic fatty liver disease and metabolic syndrome (1).
Surgery or transplant can potentially cure organ-confined primary liver cancer, but advanced disease or medical comorbidities render most patients ineligible for such treatments. Radiofrequency ablation (RFA) (2), transarterial chemoembolization (TACE) 3, 4, or systemic therapy with targeted agents like sorafenib 5, 6 can control disease and improve survival, but outcomes remain poor.
Stereotactic body radiation therapy (SBRT) refers to delivery of few (usually 3-6) doses of highly precise, conformal radiation therapy with high dose per fraction. These techniques have improved the therapeutic ratio of liver radiation therapy, with tumor control rates of 70-90% at 1-2 years reported.
Health-related quality of life (QoL) measures patients' perspectives on physical health, psychological state, independence, and social relationships (7). Because of poor long-term survival, QoL is an important posttreatment outcome to consider for liver cancer patients. Higher baseline QoL can predict improved survival 8, 9.
Literature regarding the effect of SBRT on QoL for liver cancer patients is sparse. We report QoL outcomes from a large, prospective cohort treated with SBRT for liver cancer.
Section snippets
Patients
Patients with HCC, intrahepatic cholangiocarcinoma (IC), or liver metastases (LM) were treated between March 2003 and May 2011. Eligibility and trial methodology has been described previously (10,12,13). Although the primary cohort consisted of patients with Child-Pugh A liver function, a small number of HCC patients with Child-Pugh B liver function were also treated. Institutional research ethics board approval was obtained.
Treatment
Treatment techniques have been previously described 10, 11, 12, 13, 14
Results
Of 222 treated patients, 205 were eligible for QoL analysis. Data are available for the QLQ-C30 in 205 patients and for the FACT-Hep in 196 patients. Figure 1 illustrates a Consolidated Standards of Reporting Trials diagram. Patient characteristics are summarized in Table 1. Compliance rates are summarized in Table 2. Table 3 summarizes mean QoL scores over time.
Discussion
Despite increasing utilization, and prospective studies describing favorable outcomes 10, 12, 13, 26, 27, 28, SBRT for liver cancer is still not included in practice guidelines 29, 30, 31. As acceptance grows, QoL outcomes relative to other modalities will increasingly factor into treatment decisions.
In our cohort, as in previous studies 8, 9, 23, baseline QoL significantly predicted OS. A meta-analysis (32) concluded that baseline QLQ-C30 Global Health/QoL score predicted OS for breast (P
Conclusions
Stereotactic radiation therapy for liver cancer may temporarily worsen appetite and fatigue at approximately 1 month after treatment. These effects quickly resolve, and QoL returns to baseline levels by 1 year. Other QoL domains do not show significant change from baseline after SBRT on 2 well-accepted QoL instruments. Stereotactic body radiation therapy is well-tolerated but requires comparison against other local therapies for liver cancer.
References (45)
- et al.
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
Hepatology
(2002) - et al.
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial
Lancet
(2002) - et al.
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
Lancet Oncol
(2009) - et al.
Baseline quality of life predicts survival in patients with advanced colorectal cancer
Eur J Cancer
(2002) - et al.
Assessment of residual error in liver position using kV cone-beam computed tomography for liver cancer high-precision radiation therapy
Int J Radiation Oncol Biol Phys
(2006) - et al.
Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control
Int J Radiat Oncol Biol Phys
(2005) - et al.
Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement
J Clin Epidemiol
(1997) - et al.
Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma
Ann Oncol
(2006) - et al.
Evaluating health-related quality of life in cancer clinical trials: The National Cancer Institute of Canada Clinical Trials Group experience
Value Health
(2007) - et al.
Stereotactic body radiotherapy for primary hepatocellular carcinoma
Int J Radiat Oncol Biol Phys
(2011)
Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases
Int J Radiat Oncol Biol Phys
Frameless single-session robotic radiosurgery of liver metastases in colorectal cancer patients
Eur J Cancer
Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors
Int J Radiat Oncol Biol Phys
Treatment of primary liver cancer using highly-conformal radiotherapy with kV-image guidance and respiratory control
Radiother Oncol
Health-related quality of life in patients with hepatocellular carcinoma after hepatic resection, transcatheter arterial chemoembolization, radiofrequency ablation or no treatment
Surg Oncol
Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma
Radiother Oncol
Epidemiology of primary and secondary liver cancers
Semin Intervent Radiol
Radiofrequency ablation for hepatocellular carcinoma
Int J Hyperthermia
Sorafenib in advanced hepatocellular carcinoma
N Engl J Med
Position paper from the World Health Organization
Soc Sci Med
Quality of life scores predict survival among patients with head and neck cancer
J Clin Oncol
Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma
J Clin Oncol
Cited by (57)
The Role of Stereotactic Body Radiation Therapy in the Management of Liver Metastases
2023, Seminars in Radiation OncologyHypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size
2022, Clinical Oncology
Note—An online CME test for this article can be taken at http://astro.org/MOC.
Supported by National Cancer Institute of Canada grant 18207 (L.A.D.), and a Bayer research grant paid to the institution (L.A.D.).
Conflict of interest: none.